Mounjaro, Zepbound May Lower Risk of Eye Disease in People With Diabetes

**New Hope for Diabetic Retinopathy Patients** Diabetic retinopathy, a complication of diabetes that can lead to vision loss, may be less likely to occur or worsen in patients taking tirzepatide, a medication used to manage type 2 diabetes.

**New Hope for Diabetic Retinopathy Patients**

Diabetic retinopathy, a complication of diabetes that can lead to vision loss, may be less likely to occur or worsen in patients taking tirzepatide, a medication used to manage type 2 diabetes.

Researchers have found that GLP-1 weight loss medications like Mounjaro and Zepbound, which contain the active ingredient tirzepatide, may lower the risk of diabetic retinopathy in people with type 2 diabetes.

A recent study published in Ophthalmology analyzed electronic health records from over 174,000 patients across 70 health systems in the United States. The results showed that patients taking tirzepatide had a lower risk of worsening diabetic retinopathy or related complications compared to those using lifestyle interventions alone.

According to Dr. Szilard Kiss, an ophthalmologist at NewYork-Presbyterian/Weill Cornell Medical Center and lead author of the study, "The findings suggest that patients with diabetic retinopathy may have a reduced risk of requiring more eye treatments with lasers or injections." This is a promising development for those living with diabetes and concerned about their eye health.

It's worth noting that previous research had indicated that some weight loss medications could worsen diabetic retinopathy. However, this new study suggests that tirzepatide may have a different effect, reducing the risk of complications associated with diabetic retinopathy.

Our team at [Clinic Name] is committed to staying up-to-date on the latest research and treatments for diabetes-related eye conditions. If you're living with type 2 diabetes and concerned about your eye health, we encourage you to schedule an appointment with one of our experienced ophthalmologists.